ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2772

Back Pain in Psoriatic Arthritis: Defining Prevalence, Characteristics and Performance of the Different Inflammatory Back Pain Criteria in a Psoriatic Arthritis Cohort

Kristy Yap1, Suzanne Li1, Dafna D Gladman2 and Vinod Chandran3, 1University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 2University of Toronto, Toronto, ON, Canada, 3Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Back pain and psoriatic arthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 15, 2016

Title: Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment - Poster III

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose:  Estimates of axial involvement in PsA vary from 25% to 70% depending on the inclusion criteria. Three sets of criteria are available for defining inflammatory back pain (IBP) in Ankylosing Spondylitis (AS): Calin, Rudwaleit and ASAS criteria. We aimed to determine whether these criteria are useful screening tools for axial involvement in PsA and to describe the clinical features in PsA patients with IBP, mechanical back pain (MBP), no Back Pain (BP) and silent BP.

Methods:   Patients with PsA have been followed prospectively at 6-12 month intervals according to a standard protocol since 1978. Radiographs of peripheral joints and spine are performed at 2 year intervals. All data are tracked in a computerized database.  From the database we extracted data at the first visit since 2010 on the presence of back pain, as well as criteria for IBP (Calin, Rudwaleit and ASAS). At each visit a rheumatologist also recorded whether a patient had back pain, and whether it is inflammatory or mechanical based on independent clinical judgement.  We tested the agreement between physician assessment (presence or absence of IBP) and IBP criteria. Patients whose radiographic changes met the New York (NY) Criteria for AS or had any radiographic changes consistent with sacroiliitis and/or syndesmophytes on x-ray and/or MRI were analyzed for the agreement with the presence of any BP, IBP by physician assessment, and fulfilling IBP criteria, using the Kappa coefficient.  MRI was done only if there was a suspicion of axial involvement but the x-rays were negative. Descriptive statistics are provided.

Results:   171 patients were identified from the database. The patients were mostly male (52%), mean age of onset of PsA was 43.3±13.6, and mean age at first PsA clinic visit was 46.6±13.0 years. All patients had radiographic data available at clinic entry. The prevalence for BP was 56.2% (IBP 38.01%; MBP 18.12%). 27 out of 171 (15.79%) patients with baseline x-rays fulfilled the NY radiographic criteria for AS. 45 out of 171 (26.32%) patients had any radiological sacroiliitis and/or syndesmophytes. 9 out of 31 (29.03%) patients with no axial disease on x-ray had evidence of axial disease on MRI. 18 (24.0%) of the patients with no back pain had “silent” BP (evidence of axial disease on radiology (x-ray or MRI)). The agreement (kappa coefficient) between physician assessment and IBP criteria in all patients was highest for the Calin criteria (0.81, 95% CI (0.72, 0.91)), followed by the ASAS criteria (0.72, (0.61, 0.81)), and the Rudwaleit criteria (0.71, (0.59, 0.83)). There was no significant agreement between the presence of radiographic NY criteria and the presence of back pain, physician assessment of IBP, or the IBP criteria. There was also no agreement between physician assessment of IBP and any radiographic change (syndesmophytes or sacroiliitis of at least Grade 2). Mean BASMI, BASDAI, and BASFI were highest in PsA patients with IBP than those with MBP, no BP or “silent” BP.

Conclusion:   Patients with PsA report less back pain than AS patients. The low level of agreement between physician assessment and radiological presence of axial PsA indicates that we should consider axial imaging in all patients with PsA regardless of the presence of the nature of BP.  


Disclosure: K. Yap, None; S. Li, None; D. D. Gladman, AbbVie, Amgen, BMS, Celgene Corporation, Janssen, Novartis, Pfizer, UCB, 2,AbbVie, Amgen, BMS, Celgene Corporation, Janssen, Novartis, Pfizer, UCB, 5; V. Chandran, None.

To cite this abstract in AMA style:

Yap K, Li S, Gladman DD, Chandran V. Back Pain in Psoriatic Arthritis: Defining Prevalence, Characteristics and Performance of the Different Inflammatory Back Pain Criteria in a Psoriatic Arthritis Cohort [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/back-pain-in-psoriatic-arthritis-defining-prevalence-characteristics-and-performance-of-the-different-inflammatory-back-pain-criteria-in-a-psoriatic-arthritis-cohort/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/back-pain-in-psoriatic-arthritis-defining-prevalence-characteristics-and-performance-of-the-different-inflammatory-back-pain-criteria-in-a-psoriatic-arthritis-cohort/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology